Wedbush Downgrades Javelin Pharmaceuticals (JAV) to Underperform; Lower-than-Expected Take-out Valuation
Tweet Send to a Friend
Wedbush downgrades Javelin Pharmaceuticals (NYSE Amex: JAV) from Outperform to Underperform. Price target cut from $3.50 to $1.50.
Wedbush analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
